Business Description
McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organized into four key business segments. The U.S. Pharmaceutical division plays a crucial role in the distribution of a comprehensive array of pharmaceutical products, encompassing branded, generic, specialty, biosimilar, and over-the-counter medications, alongside other health-related merchandise. This segment also delivers specialized support to community-based oncology and other specialty medical practices through practice management tools, technology solutions, clinical guidance, and broader business services. Furthermore, it assists pharmacies with consulting, outsourcing, and technology services, while also furnishing financial, operational, and clinical software solutions. Internationally, the company's dedicated segment provides distribution and support services to wholesale, institutional, and retail clients across 13 European nations and Canada. The Medical-Surgical Solutions unit is focused on supplying healthcare providers with essential medical-surgical products, sophisticated logistics management, and a variety of associated services. Finally, the Prescription Technology Solutions (RxTS) segment is designed to address complex medication challenges for patients. It collaborates with biopharmaceutical companies and life sciences partners to improve patient journeys, leveraging innovative solutions for medication access and adherence by connecting pharmacies, healthcare providers, payers, and biopharma entities. This segment further offers third-party logistics and wholesale distribution assistance. Founded in 1833, McKesson Corporation maintains its corporate headquarters in Irving, Texas.
Business History
Price Overview
Last updated: Jun 27, 2026 11:02am (just now)Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 38.55
Total Equity: -$2.17B
Shares: 124,100,000
Total Debt: $6.37B
Cash: $3.98B
EBITDA: $7.18B
Total Debt: $6.37B
Cash: $3.98B
Revenue: $403.43B
Revenue: $403.43B
Revenue: $403.43B
Total Equity: -$2.17B
Tax Rate: 17.8%
Equity: -$2.17B
Total Debt: $6.37B
Cash: $3.98B
Current Liabilities: $67.02B
Long-Term Debt: $5.11B
Total Debt: $6.37B
Total Equity: -$2.17B
Shares: 124,100,000
Shares: 124,100,000
CapEx: -$436.00M
Shares: 124,100,000
Stock Price: $763.51
Net Income: $4.76B
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
Last updated: Jun 21, 2026 6:50pm (5d ago)| Metric | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Revenue | $264.0B | $276.7B | $309.0B | $359.1B | $403.4B |
| Cost of Revenue | $251.3B | $264.8B | $296.7B | $346.6B | $388.9B |
| Gross Profit | $12.6B | $11.9B | $12.2B | $12.5B | $14.6B |
| Operating Expenses | $9.9B | $7.4B | $8.3B | $8.1B | $8.1B |
| Operating Income | $2.7B | $4.5B | $3.9B | $4.4B | $6.5B |
| Net Income | $1.1B | $3.6B | $3.0B | $3.3B | $4.8B |
| EBITDA | $3.1B | $5.7B | $4.7B | $5.3B | $7.2B |
| EPS | $7.31 | $25.23 | $22.54 | $25.86 | $38.55 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 21, 2026 6:50pm (5d ago)| Metric | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | $3.5B | $4.7B | $4.6B | $5.7B | $4.0B |
| Total Current Assets | $46.2B | $44.3B | $48.0B | $55.4B | $57.2B |
| Total Assets | $63.3B | $62.3B | $67.4B | $75.1B | $82.3B |
| Current Liabilities | $48.5B | $48.0B | $52.4B | $61.6B | $67.0B |
| Long-Term Debt | $5.1B | $4.6B | $5.6B | $4.5B | $5.1B |
| Total Liabilities | $65.1B | $63.8B | $69.0B | $76.8B | $83.2B |
| Total Equity | -$2.3B | -$1.9B | -$2.0B | -$2.1B | -$2.2B |
| Retained Earnings | $9.0B | $12.3B | $15.0B | $17.9B | $22.3B |
Cash Flow (Annual)
Last updated: Jun 21, 2026 6:50pm (5d ago)| Metric | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | $4.4B | $5.2B | $4.3B | $6.1B | $6.2B |
| Capital Expenditure | -$535.0M | -$558.0M | -$687.0M | -$859.0M | -$436.0M |
| Free Cash Flow | $3.9B | $4.6B | $3.6B | $5.2B | $5.7B |
| Acquisitions (net) | $572.0M | $210.0M | -$225.0M | $155.0M | -$2.6B |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | -$3.5B | -$3.6B | -$3.0B | -$3.1B | -$4.8B |
| Net Change in Cash | -$2.5B | $744.0M | -$94.0M | $1.4B | -$2.0B |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 11:02am (just now)| Metric | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|
| Revenue |
$464.0B $459.7B – $475.9B
|
$501.6B $500.5B – $502.8B
|
$530.6B $520.8B – $542.0B
|
$595.9B $584.8B – $608.7B
|
| EBITDA |
$7.4B $7.4B – $7.6B
|
$8.0B $8.0B – $8.0B
|
$8.5B $8.3B – $8.7B
|
$9.5B $9.4B – $9.7B
|
| Net Income |
$6.3B $6.2B – $6.3B
|
$7.2B $7.0B – $7.3B
|
$8.3B $8.1B – $8.5B
|
$9.8B $9.5B – $10.0B
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 21, 2026 6:50pm (5d ago)| Metric | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Revenue Growth | +4.8% | +11.7% | +16.2% | +12.4% |
| Gross Profit Growth | -6.2% | +2.8% | +2.3% | +16.5% |
| Operating Income Growth | +63.5% | -11.8% | +11.3% | +47.6% |
| Net Income Growth | +219.6% | -15.7% | +9.8% | +44.5% |
| EBITDA Growth | +84.6% | -18.6% | +12.5% | +36.7% |
Insider Trading (Recent)
All SEC Form 4 codes
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-17 | TYLER BRIAN S. | S-Sale | 8,463.00 | $775.13 | $6.6M |
| 2026-06-09 | TYLER BRIAN S. | S-Sale | 4,929.00 | $763.00 | $3.8M |
| 2026-06-05 | Rutledge Napoleon B JR | S-Sale | 133.00 | $764.00 | $101,612 |
| 2026-06-01 | Rodgers Thomas L | S-Sale | 123.00 | $735.50 | $90,467 |
| 2026-06-02 | Rodgers Thomas L | S-Sale | 699.00 | $735.27 | $513,954 |
| 2026-06-01 | Smith LeAnn B | S-Sale | 1,810.00 | $735.50 | $1.3M |
| 2026-05-29 | Cheung Kenny K | A-Award | 8,082.00 | $0.00 | $0 |
| 2026-05-29 | Cheung Kenny K | A-Award | 3,019.00 | $0.00 | $0 |
| 2026-05-29 | Cheung Kenny K | 0.00 | $0.00 | $0 | |
| 2026-05-26 | Lau Michele | S-Sale | 3,550.00 | $761.09 | $2.7M |
| 2026-05-23 | TYLER BRIAN S. | M-Exempt | 4,579.00 | $0.00 | $0 |
| 2026-05-23 | TYLER BRIAN S. | F-InKind | 1,831.00 | $766.08 | $1.4M |
| 2026-05-23 | TYLER BRIAN S. | M-Exempt | 4,579.00 | $0.00 | $0 |
| 2026-05-23 | Vitalone Britt J. | M-Exempt | 1,476.00 | $0.00 | $0 |
| 2026-05-23 | Vitalone Britt J. | F-InKind | 581.00 | $766.08 | $445,092 |
| 2026-05-23 | Vitalone Britt J. | M-Exempt | 1,476.00 | $0.00 | $0 |
| 2026-05-23 | Smith LeAnn B | M-Exempt | 679.00 | $0.00 | $0 |
| 2026-05-23 | Smith LeAnn B | F-InKind | 268.00 | $766.08 | $205,309 |
| 2026-05-23 | Smith LeAnn B | M-Exempt | 679.00 | $0.00 | $0 |
| 2026-05-23 | Rodgers Thomas L | M-Exempt | 594.00 | $0.00 | $0 |
Dividend History (Last 20)
Last updated: Jun 21, 2026 6:50pm (5d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-06-01 | $0.82 | 2026-04-21 | 2026-06-01 | 2026-07-01 |
| 2026-03-02 | $0.82 | 2026-01-28 | 2026-03-02 | 2026-04-01 |
| 2025-12-01 | $0.82 | 2025-10-30 | 2025-12-01 | 2026-01-02 |
| 2025-09-02 | $0.82 | 2025-07-30 | 2025-09-02 | 2025-10-01 |
| 2025-06-02 | $0.71 | 2025-05-01 | 2025-06-02 | 2025-07-01 |
| 2025-03-03 | $0.71 | 2025-01-30 | 2025-03-03 | 2025-04-01 |
| 2024-12-02 | $0.71 | 2024-10-31 | 2024-12-02 | 2025-01-02 |
| 2024-08-30 | $0.71 | 2024-08-01 | 2024-09-02 | 2024-10-01 |
| 2024-06-03 | $0.62 | 2024-04-24 | 2024-06-03 | 2024-07-01 |
| 2024-02-29 | $0.62 | 2024-02-01 | 2024-03-01 | 2024-04-01 |
| 2023-11-30 | $0.62 | 2023-10-26 | 2023-12-01 | 2024-01-02 |
| 2023-08-31 | $0.62 | 2023-07-24 | 2023-09-01 | 2023-10-02 |
| 2023-05-31 | $0.54 | 2023-04-27 | 2023-06-01 | 2023-07-03 |
| 2023-02-28 | $0.54 | 2023-01-26 | 2023-03-01 | 2023-04-03 |
| 2022-11-30 | $0.54 | 2022-10-26 | 2022-12-01 | 2023-01-03 |
| 2022-08-31 | $0.54 | 2022-07-22 | 2022-09-01 | 2022-10-03 |
| 2022-05-31 | $0.47 | 2022-04-27 | 2022-06-01 | 2022-07-01 |
| 2022-02-28 | $0.47 | 2022-01-27 | 2022-03-01 | 2022-04-01 |
| 2021-11-30 | $0.47 | 2021-10-28 | 2021-12-01 | 2022-01-03 |
| 2021-08-31 | $0.47 | 2021-07-26 | 2021-09-01 | 2021-10-01 |
Narrative Economics
market-narrative step).